For years, a daily nap has been treated as one of the small comforts of getting older. But a study published in early 2026 in JAMA, drawing on more than a decade of objective sleep tracking among older Americans, found that the habit may carry a warning. Older adults who napped frequently and for longer stretches during the day faced meaningfully higher rates of cardiovascular events and steeper cognitive decline compared with peers who napped rarely or not at all.
The research came out of the Rush Memory and Aging Project (MAP), a long-running study based at Rush University Medical Center in Chicago that has followed community-dwelling adults aged 65 and older since 1997. What set this analysis apart from earlier napping research was its measurement tool: instead of asking participants how often they napped, investigators strapped actigraph devices to their wrists, recording movement around the clock for up to 14 consecutive days per assessment period. The result was a granular, objective record of when participants were asleep during daylight hours, sidestepping the well-documented problem that people routinely underestimate or forget short daytime sleep episodes.
How the study measured napping
The actigraphs used in the study classify sleep and wake states using the Cole-Kripke algorithm, a scoring method originally validated against polysomnography, the gold standard of clinical sleep measurement. A separate validation study in the algorithm’s citation trail further confirmed that wrist-worn accelerometers can reliably distinguish sleep from quiet wakefulness in older populations.
That technical foundation matters because most prior studies linking naps to health outcomes relied on questionnaires. Self-reported nap data tend to miss brief or unintentional dozing, which can skew results. By capturing every daytime sleep episode of five minutes or longer, the JAMA researchers built a dataset that reflects actual behavior rather than recalled impressions of behavior.
Participants wore the devices during normal daily routines at home, not in a sleep lab, which means the data reflect real-world napping patterns rather than artificial conditions. Annual clinical assessments, standardized cognitive testing, and, for consenting participants, eventual brain autopsy rounded out the picture, giving investigators the ability to connect sleep behavior measured years earlier to both clinical outcomes and physical brain changes.
What the findings showed
The central finding was a dose-response pattern: the more frequently participants napped and the longer those naps lasted, the stronger the statistical association with adverse outcomes. Adults in the highest napping category faced elevated rates of heart attack, stroke, and heart failure compared with those who napped infrequently. Cognitive decline followed a similar gradient, with frequent nappers showing faster deterioration on tests of episodic memory and global cognition over the follow-up period.
Importantly, these associations held after the researchers adjusted for nighttime sleep duration, sleep fragmentation, age, sex, education, body mass index, depression, and several chronic conditions. That adjustment process does not eliminate the possibility of unmeasured confounders, but it does mean the napping signal was not simply a proxy for poor nighttime sleep or obvious comorbidities.
The study did not, however, establish that napping causes cardiovascular events or cognitive decline. Observational research, no matter how carefully designed, cannot prove causation. Frequent daytime sleep could be an early symptom of neurodegeneration, a consequence of undiagnosed sleep apnea, a side effect of sedating medications, or a behavioral response to depression, rather than an independent driver of harm.
What the study cannot answer
Several questions remain open. The JAMA paper did not report whether specific nap durations crossed a threshold from benign to concerning, a detail clinicians and patients will want. It also did not publish data linking nap patterns directly to Alzheimer’s-related biomarkers such as amyloid plaques or tau tangles, even though MAP’s autopsy-based design could eventually provide that connection in future analyses.
The cohort itself carries limits. MAP participants are predominantly white, well-educated, and research-engaged enough to consent to annual testing and organ donation. That profile may not reflect the broader aging population, particularly older adults in institutional care, those from underrepresented racial and ethnic groups, or people in cultures where afternoon napping is a longstanding norm. Whether the same associations would appear in a Mediterranean cohort accustomed to daily siestas, for example, is unknown.
No randomized controlled trial has ever assigned older adults to nap or abstain from napping and then tracked cardiovascular and cognitive outcomes over years. Such a trial would face enormous practical and ethical hurdles, which means observational evidence like the JAMA study is likely to remain the strongest available data for the foreseeable future. The Rush Alzheimer’s Disease Center does make limited datasets from MAP available to outside investigators through a formal data-request process, opening the door for independent replication or reanalysis.
What clinicians and families can do now
The practical message is cautious, not alarmist. A short, intentional nap after lunch is a common feature of aging and is not clearly harmful on its own. The signal from this research points to a narrower concern: frequent, prolonged, or unplanned daytime sleep, especially when it represents a change from a person’s usual pattern, may be worth investigating rather than dismissing.
In a clinical setting, that means questions about daytime sleepiness deserve more than a shrug. When an older patient reports dozing off repeatedly during quiet activities, or a family member notices the person falling asleep at unusual times, that information can prompt a closer look. Possible contributors include fragmented nighttime sleep, medication side effects, mood disorders, sleep-disordered breathing, or the earliest stages of neurodegenerative disease.
Because the evidence does not prove that reducing naps will lower cardiovascular or cognitive risk, the most defensible approach is to treat napping as a potential signal rather than a confirmed treatment target. For some patients, consolidating nighttime sleep through better sleep hygiene or treatment of underlying conditions may naturally reduce daytime drowsiness. For others, particularly those with established cognitive impairment, structured short naps may still be appropriate as part of supportive care.
Where the research goes from here
The combination of validated actigraphy, a deeply characterized cohort, and transparent data governance makes the 2026 JAMA analysis one of the strongest entries in a growing body of research on napping and late-life health. But it does not close the debate. Future studies that tie nap patterns to specific neuropathologic findings at autopsy, clarify how much nap frequency simply mirrors nighttime sleep quality, and test whether modifying nap behavior changes outcomes will all be needed before clinical guidelines can be written with confidence.
Until then, the most useful stance for older adults and the people who care for them is watchful attention. Neither treating every afternoon doze as a red flag nor ignoring a new pattern of excessive daytime sleep fits what the science currently supports. Napping, it turns out, may be one of the more accessible windows into how the aging brain and heart are doing. The challenge now is learning to read what it reveals.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
